In the quarter, the collaboration profit-sharing was a net expense of $54 million, which included $53 million of net profit-sharing expense related to Biogen's biosimilar collaboration with Samsung Bioepis and approximately $1 million of net profit-sharing expense related to Biogen's collaboration with Sage Therapeutics related to the commercialization of Zurzuvae in the United States. On the fourth-quarter conference call, Biogen said the Initial launch uptake of Zurzuvae has exceeded management's expectations. No shares were repurchased in the fourth quarter of 2023.